Figure 5
Clinical outcome for non-APL AML patients stratified according to FLT3/TKD mutant level. (A) CIR and (B) OS. High-level mutations, more than 25% of FLT3 alleles; low-level mutations, 25% of FLT3 alleles or less.
Clinical outcome for non-APL AML patients stratified according to FLT3/TKD mutant level. (A) CIR and (B) OS. High-level mutations, more than 25% of FLT3 alleles; low-level mutations, 25% of FLT3 alleles or less.
